Vishee Medical

Vishee Medical has established itself as a leading Chinese manufacturer of rehabilitation medical devices since its founding in 2001. Listed on Shanghai’s STAR Market (688580.SH), the company develops products across magnetic stimulation, electrical stimulation, electrophysiology, and rehabilitation robotics platforms, with particular strength in pelvic floor and neurological rehabilitation applications.

Company Overview

Headquartered in Nanjing’s Yuhuatai District, Vishee Medical operates as a technology-driven medical device company focused on applying advanced technologies to improve patient quality of life. The company has built six core technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, rehabilitation robotics, radiofrequency, and laser technologies.

Vishee holds a dominant position in China’s pelvic floor rehabilitation market, having pioneered the domestic development of pelvic floor magnetic stimulation devices. The company serves as both an industry leader and standard-setter in this specialized field, with over two decades of accumulated clinical experience and market presence.

Core Products

Magnetic Stimulation Systems

Vishee’s magnetic stimulation platform encompasses three major product lines:

MagNeuro Series — Transcranial magnetic stimulation (TMS) systems for psychiatric and neurological rehabilitation. The second-generation TMS devices offer 4-channel switching capability, while the MagNeuro ONE system (approved March 2024) integrates TMS with MRI imaging for precision-guided neurostimulation.

MagBelle Series — Pelvic floor magnetic stimulation devices for urinary incontinence and postpartum rehabilitation. The MagBelle AF180 received FDA 510(k) clearance in September 2023 (K230767).

MagGraver — Body contouring magnetic stimulator approved by FDA (March 2023) and NMPA (November 2023), representing the only domestically developed magnetic body-shaping device validated through large-scale clinical trials.

Rehabilitation Robotics

The company has developed a rehabilitation robot portfolio covering upper and lower extremity training:

Xlocom System — Intelligent rehabilitation training platform for motor function recovery

Lower Limb Exoskeleton Robot — Gait training system included in medical insurance programs across 18 Chinese provinces, deployed in over 300 tertiary hospitals

Upper Limb Rehabilitation Robots — Systems for stroke and neurological injury recovery

Electrical Stimulation and Biofeedback

The SA980X, Myotrac, and Ruiyi series biostimulation feedback instruments serve pelvic floor rehabilitation, mental health, and general rehabilitation applications. Vishee holds the largest number of NMPA-registered biofeedback products in China.

Technology & Innovation

Vishee’s research priorities center on integrating artificial intelligence with rehabilitation technologies. Current development areas include:

• AI-powered real-time analysis of biofeedback data for anxiety, ADHD, and depression
• Brain-computer interface integration with rehabilitation robotics
• Closed-loop cognitive training systems for Alzheimer’s and brain injury patients
• Functional electrical stimulation triggered by decoded motor intention

The MagNeuro ONE system exemplifies this innovation direction, combining TMS with MRI-based navigation to achieve precise targeting of brain regions. The system completes motor threshold measurement in 2 minutes and MRI image processing in 3 minutes.

Market Presence

Vishee’s products serve rehabilitation departments, psychiatric facilities, obstetrics and gynecology centers, and specialized rehabilitation hospitals throughout China. The company’s lower limb exoskeleton robot has achieved particularly broad adoption, covering over 300 Class III hospitals and securing inclusion in 18 provincial medical insurance catalogs.

The company reported trailing twelve-month revenue of approximately $60 million as of September 2025, with market capitalization around $620 million. Key growth drivers include the MagNeuro ONE navigation system, body contouring magnetic devices, and radiofrequency products.

International expansion remains in early stages, with the company targeting completion of initial overseas product registrations by late 2026.

Key Milestones

• 2001: Company founded in Nanjing
• 2020: Listed on Shanghai STAR Market (688580.SH)
• 2022: Acquired Hefei Korida Laser, adding holmium laser technology
• 2023-03: MagGraver body contouring system receives FDA clearance
• 2023-09: MagBelle AF180 receives FDA 510(k) clearance (K230767)
• 2023-11: MagGraver receives NMPA registration certificate
• 2024-03: MagNeuro ONE TMS navigation robot receives NMPA Class III certificate
• 2024-09: PicoV picosecond laser system receives NMPA approval
• 2024: Shockwave therapy device receives NMPA approval

Frequently Asked Questions

What products does Vishee Medical manufacture?

Vishee produces rehabilitation medical devices across six technology platforms: magnetic stimulation (TMS systems, pelvic floor stimulators, body contouring devices), electrical stimulation (biofeedback instruments), electrophysiology, rehabilitation robotics (upper/lower limb exoskeletons), radiofrequency devices, and laser systems (holmium laser, picosecond laser).

Is Vishee Medical publicly traded?

Yes, Vishee Medical trades on Shanghai’s STAR Market under stock code 688580.SH. The company completed its IPO in 2020.

Does Vishee have FDA-cleared products?

Yes, Vishee has received FDA 510(k) clearance for the MagBelle AF180 pelvic floor muscle stimulator (K230767, September 2023) and the MagGraver body contouring magnetic stimulator (March 2023).

What is Vishee’s position in China’s rehabilitation market?

Vishee holds a leading position in pelvic floor rehabilitation and transcranial magnetic stimulation markets. The company’s lower limb exoskeleton robot has been deployed in over 300 Class III hospitals and is covered by medical insurance in 18 provinces.